InflaRx N.V.
IFRXDrugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
2dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
IFRX Earnings Report
EPS Est: $-0.08 | FQ end 2026-06
IFX-1 + BSC
Severe COVID-19 Pneumonia
vilobelimab
Pyoderma Gangrenosum
Glucocorticoid (GC)
Granulomatosis With Polyangiitis (GPA)
CaCP29
Severe Sepsis
IFX-1
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IFX-1 + BSC | Phase 3 | Severe COVID-19 Pneumonia | - | - |
vilobelimab | Phase 2 | Pyoderma Gangrenosum | - | - |
Glucocorticoid (GC) | Phase 2 | Granulomatosis With Polyangiitis (GPA) | - | - |
CaCP29 | Phase 2 | Severe Sepsis | - | - |
IFX-1 | Phase 2 | Hidradenitis Suppurativa | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in InflaRx N.V.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in InflaRx N.V.'s (IFRX) pipeline across Phase 3, Phase 2. Its lead program is IFX-1 + BSC (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is InflaRx N.V.'s next FDA catalyst?→
InflaRx N.V.'s (IFRX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IFRX biotech catalysts?→
Add IFRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow InflaRx N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.